Hartnett Jack, Jaber Wael, Maurer Matthew, Sperry Brett, Hanna Mazen, Collier Patrick, Patel Divyang R, Wazni Oussama M, Donnellan Eoin
Department of Medicine, Trinity College Dublin, Dublin, Ireland.
Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
JACC CardioOncol. 2021 Oct 19;3(4):506-515. doi: 10.1016/j.jaccao.2021.07.010. eCollection 2021 Oct.
Cardiac amyloidosis (CA) is an infiltrative cardiomyopathy caused by the extracellular deposition of amyloid fibrils in the myocardium. Although cardiac amyloidosis patients primarily present with heart failure symptoms, arrhythmias and conduction system disease are frequently encountered. Atrial fibrillation (AF) is observed in up to 70% of patients at the time of diagnosis, and patients typically have controlled ventricular rates caused by concomitant conduction system disease. Thromboembolic risk is particularly high in patients with CA and AF, and left atrial thrombi have been observed even in the absence of clinically diagnosed AF. Atrioventricular nodal and infra-Hisian disease are common, and permanent pacemakers are frequently required. The use of implantable cardioverter-defibrillators in this population is controversial. This review summarizes the published data and therapeutic strategies surrounding arrhythmias and conduction system disease with the goal of aiding clinicians managing the clinical complexities of CA.
心脏淀粉样变性(CA)是一种浸润性心肌病,由淀粉样纤维在心肌细胞外沉积所致。虽然心脏淀粉样变性患者主要表现为心力衰竭症状,但心律失常和传导系统疾病也很常见。诊断时高达70%的患者会出现心房颤动(AF),且患者通常因合并传导系统疾病而心室率得到控制。CA合并AF的患者血栓栓塞风险特别高,甚至在无临床诊断AF的情况下也观察到左心房血栓。房室结和希氏束以下疾病很常见,常需要植入永久性起搏器。在这一人群中使用植入式心脏复律除颤器存在争议。本综述总结了关于心律失常和传导系统疾病的已发表数据及治疗策略,旨在帮助临床医生应对CA的临床复杂性。